Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Teerlink, JR; Diaz, R; Felker, GM; McMurray, JJV; Metra, M; Solomon, SD; Adams, KF; Anand, I; Arias-Mendoza, A; Biering-Sorensen, T; Bohm, M; Bonderman, D; Cleland, JGF; Corbalan, R; Crespo-Leiro, MG; Dahlstrom, U; Echeverria, LE; Fang, JMC; Filippatos, G; Fonseca, C; Goncalvesova, E; Goudev, AR; Howlett, JG; Lanfear, DE; Li, J; Lund, M; Macdonald, P; Mareev, V; Momomura, SI; O'Meara, E; Parkhomenko, A; Ponikowski, P; Ramires, FJA; Serpytis, P; Sliwa, K; Spinar, J; Suter, TM; Tomcsanyi, J; Vandekerckhove, H; Vinereanu, D; Voors, AA; Yilmaz, MB; Zannad, F; Sharpsten, L; Legg, JC; Varin, C; Honarpour, N; Abbasi, SA; Malik, FI; Kurtz, CE

Teerlink, JR (corresponding author), San Francisco VA Med Ctr, Cardiol, 111C,Bldg 203,Rm 2A-49,4150 Clement St, San Francisco, CA 94121 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2021; 384 (2): 105

Abstract

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower inci......

Full Text Link